Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

117 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nanoparticle display of prefusion coronavirus spike elicits S1-focused cross-reactive protection across divergent subgroups.
Hutchinson G, Abiona O, Ziwawo C, Werner A, Ellis D, Tsybovsky Y, Leist S, Palandjian C, West A, Fritch E, Wang N, Wrapp D, Boyoglu-Barnum S, Ueda G, Baker D, Kanekiyo M, McLellan J, Baric R, King N, Graham B, Corbett K. Hutchinson G, et al. Among authors: kanekiyo m. Res Sq [Preprint]. 2022 Nov 7:rs.3.rs-2199814. doi: 10.21203/rs.3.rs-2199814/v1. Res Sq. 2022. Update in: Nat Commun. 2023 Oct 4;14(1):6195. doi: 10.1038/s41467-023-41661-4 PMID: 36380759 Free PMC article. Updated. Preprint.
Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine.
Casazza JP, Hofstetter AR, Costner PJM, Holman LA, Hendel CS, Widge AT, Wu RL, Whalen WR, Cunningham J, Arthur A, Wang X, Ola A, Saunders J, Mendoza F, Novik L, Burgos Florez MC, Ortega-Villa AM, Apte PJ, Strom L, Wang L, Imam M, Basappa M, Naisan M, Castro M, Trost JF, Narpala SR, Vanderven HA, Yamshchikov GV, Berkowitz NM, Gordon IJ, Plummer SH, Wycuff DL, Vazquez S, Gillespie RA, Creanga A, Adams WC, Carlton K, Gall JG, McDermott AB, Serebryannyy LA, Houser KV, Koup RA, Graham BS, Ledgerwood JE, Mascola JR, Pierson TC, Andrews SF, Kanekiyo M, Dropulic LK; VRC 323 study team. Casazza JP, et al. Among authors: kanekiyo m. NPJ Vaccines. 2024 Sep 17;9(1):171. doi: 10.1038/s41541-024-00959-0. NPJ Vaccines. 2024. PMID: 39289377 Free PMC article.
An influenza H1 hemagglutinin stem-only immunogen elicits a broadly cross-reactive B cell response in humans.
Andrews SF, Cominsky LY, Shimberg GD, Gillespie RA, Gorman J, Raab JE, Brand J, Creanga A, Gajjala SR, Narpala S, Cheung CSF, Harris DR, Zhou T, Gordon I, Holman L, Mendoza F, Houser KV, Chen GL, Mascola JR, Graham BS, Kwong PD, Widge A, Dropulic LK, Ledgerwood JE, Kanekiyo M, McDermott AB. Andrews SF, et al. Among authors: kanekiyo m. Sci Transl Med. 2023 Apr 19;15(692):eade4976. doi: 10.1126/scitranslmed.ade4976. Epub 2023 Apr 19. Sci Transl Med. 2023. PMID: 37075126 Clinical Trial.
Next-Generation Influenza Vaccines.
Kanekiyo M, Graham BS. Kanekiyo M, et al. Cold Spring Harb Perspect Med. 2021 Aug 2;11(8):a038448. doi: 10.1101/cshperspect.a038448. Cold Spring Harb Perspect Med. 2021. PMID: 32229612 Free PMC article. Review.
An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults.
Widge AT, Hofstetter AR, Houser KV, Awan SF, Chen GL, Burgos Florez MC, Berkowitz NM, Mendoza F, Hendel CS, Holman LA, Gordon IJ, Apte P, Liang CJ, Gaudinski MR, Coates EE, Strom L, Wycuff D, Vazquez S, Stein JA, Gall JG, Adams WC, Carlton K, Gillespie RA, Creanga A, Crank MC, Andrews SF, Castro M, Serebryannyy LA, Narpala SR, Hatcher C, Lin BC, O'Connell S, Freyn AW, Rosado VC, Nachbagauer R, Palese P, Kanekiyo M, McDermott AB, Koup RA, Dropulic LK, Graham BS, Mascola JR, Ledgerwood JE; VRC 321 study team. Widge AT, et al. Among authors: kanekiyo m. Sci Transl Med. 2023 Apr 19;15(692):eade4790. doi: 10.1126/scitranslmed.ade4790. Epub 2023 Apr 19. Sci Transl Med. 2023. PMID: 37075129 Free PMC article. Clinical Trial.
Co-immunization with hemagglutinin stem immunogens elicits cross-group neutralizing antibodies and broad protection against influenza A viruses.
Moin SM, Boyington JC, Boyoglu-Barnum S, Gillespie RA, Cerutti G, Cheung CS, Cagigi A, Gallagher JR, Brand J, Prabhakaran M, Tsybovsky Y, Stephens T, Fisher BE, Creanga A, Ataca S, Rawi R, Corbett KS, Crank MC, Karlsson Hedestam GB, Gorman J, McDermott AB, Harris AK, Zhou T, Kwong PD, Shapiro L, Mascola JR, Graham BS, Kanekiyo M. Moin SM, et al. Among authors: kanekiyo m. Immunity. 2022 Dec 13;55(12):2405-2418.e7. doi: 10.1016/j.immuni.2022.10.015. Epub 2022 Nov 9. Immunity. 2022. PMID: 36356572 Free PMC article.
Corrigendum: Impact of adjuvant: trivalent vaccine with quadrivalent-like protection against heterologous Yamagata-lineage influenza B virus.
Myers ML, Gallagher JR, Woolfork DD, Stradtmann-Carvalho RK, Maldonado-Puga S, Bock KW, Boyoglu-Barnum S, Syeda H, Creanga A, Alves DA, Kanekiyo M, Harris AK. Myers ML, et al. Among authors: kanekiyo m. Front Immunol. 2023 Sep 12;14:1283355. doi: 10.3389/fimmu.2023.1283355. eCollection 2023. Front Immunol. 2023. PMID: 37771593 Free PMC article.
117 results